Please login to the form below

Not currently logged in
Email:
Password:

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

Pfizer

Data from a trial of Pfizer’s gene therapy for Duchenne muscular dystrophy (DMD) have shown signs of efficacy, but also safety concerns that sparked an uptick in shares for rival developers.

The data came from six of a planned population of 12 patients aged 5 to 12 in the phase 1b study of PF-06939926, and produced the headline news of  a serious immune reaction in one child on the trial.

This involved an acute kidney injury, haemolysis, and reduced platelet count and required hospitalisation in intensive care, dialysis and treatment with Alexion’s kidney drug Soliris (eculizumab).

Other side effects including nausea, vomiting and fever were seen in four of the six patients. In three of the children, nausea/vomiting could be controlled with oral anti-emetic drugs, but in one case the side effects were so bad the patient had to be hospitalised for two days.

There were signs of efficacy, with the gene therapy achieving expression levels of ‘mini-dystrophin’ – a truncated form of the protein that is deficient in DMD – in the 10% to 60% of normal range, depending on the dose administered.

Two patients had at least one year of follow-up and showed modest increases in the NorthStar Ambulatory Assessment (NSAA) scale, used to assess symptoms caused by the muscle-wasting disease. Typically children with DMD would have stable NSAA scores or see a slight decline over that timeframe.

Pfizer is vying with Sarepta and Solid Biosciences to bring a gene therapy for DMD through development, and inevitably the side-effect issue buoyed its rivals, even though all the patients in the phase 1b trial made a full recovery.

Shares in Sarepta – which already markets a drug to treat DMD and reported encouraging results with its AAVrh74.MHCK7 candidate last year – closed up 17% ahead of the weekend and made additional gains after hours.

Solid Bio meanwhile gained almost 14%, despite posting what were seen as disappointing dystrophin expression levels in a phase 1/2 trial of its SGT-001 DMD gene therapy candidate earlier this year.

Pfizer adopted a cautious tone in its assessment of the data, with Seng Chen, chief scientific officer for the company’s rare disease unit, saying the results “may exemplify the potential for this modality to change patients’ lives.”

The company is however pressing ahead with plans for a pivotal trial of PF-06939926, currently expected to get underway in the first half of 2020.

According to Reuters, both the hospitalisations occurred in patients on the highest dose of the gene therapy, which also produced the most robust improvements in dystrophin expression.

Pfizer has said it will test the higher dose in its upcoming phase 3 trial, possibly alongside an intermediate dose, and will include strategies to reduce the risk of side effects.

Article by
Phil Taylor

1st July 2019

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics